| |
| |
Other news for:
•
•
|
| | Resources from
|
Abraxane Approved to Treat Advanced Lung Cancer
Among people who aren't candidates for surgery or radiation
By Scott Roberts
FRIDAY, Oct. 12 (HealthDay News) -- Abraxane (paclitaxel protein-bound) has been approved by the U.S. Food and Drug Administration -- in combination with the drug carboplatin -- to treat advanced or spreading non-small cell lung cancer among people who aren't candidates for surgery or radiation therapy, the agency said Friday.
Abraxane was first approved in 2005 to treat breast cancer.
In a new clinical study of 1038 people, the most common adverse reactions to the drug were anemia, loss of hair, nausea, fatigue, loss of appetite, irregularity, rash and swelling.
Abraxane is produced by Celgene Corp., based in Summit, N.J.
More information
To learn more about non-small cell lung cancer, visit the U.S. .
Copyright © 2012 . All rights reserved.
URL:http://www.healthscout.com/template.asp?id=669623
Resources from HONselect:
HONselect is the HON's medical search engine.
It retrieves scientific articles, images, conferences and web sites on the
selected subject.
The list of medical terms above are retrieved automatically from the article.
|
Disclaimer:
The text presented on this page is not a substitute for professional
medical advice. It is for your information only and may not represent your true
individual medical situation. Do not hesitate to consult your healthcare provider
if you have any questions or concerns. Do not use this information to diagnose or
treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources
and may not reflect your own country regulations.
The Health On the Net Foundation does not endorse opinions,
products, or services that may appear in HealthDay articles.
|
|
